Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Marine Microbe Could Help Clear Chronic Sinusitis

By BiotechDaily International staff writers
Posted on 06 Mar 2013
Image: The bacterium Bacillus licheniformis (Photo courtesy of Newcastle University).
Image: The bacterium Bacillus licheniformis (Photo courtesy of Newcastle University).
An enzyme isolated from the marine bacterium Bacillus licheniformis incorporated into a nasal spray could help relieve chronic rhinosinusitis (CRS), according to a new study.

Researchers at Newcastle University (United Kingdom) collected mucous and sinus biopsy samples from 20 different patients, isolating between two and six different species of bacteria from each individual. In the laboratory, 24 different strains were investigated, all of which produced a slimy protective biofilm made up of a mass of bacteria held in a web of extracellular DNA that bind the bacteria to each other. This clumping protects the bacteria from attack by antibiotics, making it very difficult to clear them from the sinuses.

Based on previous studies of the marine bacterium—investigated as a tool for cleaning ship hulls—the researchers found that when the bacteria want to move, they release a deoxyribonuclease enzyme, called NucB, which breaks down the external DNA, resulting in dissolution of the biofilm and release of the bacteria. When NucB was purified and added to 14 other biofilms, the researchers succeeded in quickly dissolving the slimy biofilm, exposing the bacteria and leaving them vulnerable. The study was published on February 19, 2013, in PLOS One.

“In effect, the enzyme breaks down the extracellular DNA, which is acting like a glue to hold the cells to the surface of the sinuses. In the lab, NucB cleared over half of the organisms we tested,” said corresponding author Nicholas Jakubovics, PhD, of Newcastle University.

“For many people, symptoms include a blocked nose, nasal discharge, or congestion, recurrent headaches, loss of the sense of smell and facial pain,” added Mr. Mohamed Reda Elbadawey, a consultant of Otolaryngology Head and Neck Surgery at the Newcastle Hospitals NHS Foundation Trust (United Kingdom). “While steroid nasal sprays and antibiotics can help some people, for the patients I see, they have not been effective and these patients have to undergo the stress of surgery. If we can develop an alternative we could benefit thousands of patients a year.”

Persistent colonization of microbial biofilms is a major factor in the pathogenesis of CRS, with obstructive mucin biofilms detected on the mucosa in the paranasal sinuses, with or without polyps, and in the absence of other symptoms that would indicate fungal rhinosinusitis. The removal of this mucin, which is extremely tenacious, is the cornerstone of surgical treatment of CRS.

Related Links:

Newcastle University
Newcastle Hospitals NHS Foundation Trust



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A scheme for the generation of induced pluripotent stem cells (IPSC). (1) Isolate and culture donor cells. (2) Transfect stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3)  Harvest and culture the cells using mitotically inactivated feeder cells. (4) A small subset of the transfected cells forms iPSC cell colonies (Photo courtesy of Wikimedia Commons).

Innovative Technique Produces More Reliable Pluripotent Stem Cells

A recent paper described a more reliable way to induce the formation of pluripotent stem cells (iPSCs) from adult cells in a mouse model. Reliable high-quality iPSCs are needed for the development of... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.